The palliative role of PDT in recurrent advanced nasopharyngeal carcinoma: Case series

Abbas, Syedda; Jerjes, Waseem; Upile, Tahwinder; Vaz, Francis; Hopper, Colin

doi:10.1016/j.pdpdt.2012.01.004

Cited by 15 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also interesting is the use of PDT for more advanced lesions of NPC. PDT showed clinical benefit in a certain number of patients with recurrent advanced local NPC [6,19,25]. The exact mechanism of these outstanding responses remains uncertain, since full illumination of the tumour surface and depth penetration was not possible.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Photodynamic therapy as salvage therapy for patients with nasopharyngeal carcinoma experiencing local failures following definitive radiotherapy

Stoker

Indrasari

Herdini

et al. 2015

Photodiagnosis and Photodynamic Therapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…PDT can be performed under local anaesthesia. A number of studies showed good clinical response with acceptable side effects when treating head and neck carcinomas, including nasopharyngeal carcinomas [14][15][16][17][18][19]. However PDT has not yet been integrated to routine treatment regimes.…”

Section: Introductionmentioning

confidence: 99%

Photodynamic therapy as salvage therapy for patients with nasopharyngeal carcinoma experiencing local failures following definitive radiotherapy

Stoker

Indrasari

Herdini

et al. 2015

Photodiagnosis and Photodynamic Therapy

View full text Add to dashboard Cite

“…The prominent adverse events in the immediate post PDT phase include treatment-site pain and swelling. A number of studies reported that pain is commonly experienced at certain stage following PDT by nearly most patients [18,[35][36][37][38]. However, most pain arises around 24-48 h following the end of light delivery and can last for up to 14 days.…”

Section: Introductionmentioning

confidence: 99%

Photochemical Internalization for Intracellular Drug Delivery. From Basic Mechanisms to Clinical Research

Jerjes¹,

Theodossiou

Hirschberg

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Photochemical internalisation (PCI) is a unique intervention which involves the release of endocytosed macromolecules into the cytoplasmic matrix. PCI is based on the use of photosensitizers placed in endocytic vesicles that, following light activation, lead to rupture of the endocytic vesicles and the release of the macromolecules into the cytoplasmic matrix. This technology has been shown to improve the biological activity of a number of macromolecules that do not readily penetrate the plasma membrane, including type I ribosome-inactivating proteins (RIPs), gene-encoding plasmids, adenovirus and oligonucleotides and certain chemotherapeutics, such as bleomycin. This new intervention has also been found appealing for intracellular delivery of drugs incorporated into nanocarriers and for cancer vaccination. PCI is currently being evaluated in clinical trials. Data from the first-in-human phase I clinical trial as well as an update on the development of the PCI technology towards clinical practice is presented here.

show abstract

“…This therapeutic modality has been used in clinics to treat various medical conditions such as localized infections, skin diseases, premalignant and malignant disorders [15,16]. PDT has been employed in the management of nasopharyngeal carcinoma [17,18], sarcomas [19], and vascular anomalies [20,21]. PS activation by light irradiation generates reactive oxygen species, especially singlet oxygen, resulting in cellular damage and death [22].…”

Section: Introductionmentioning

confidence: 99%

A Novel Treatment Modality for Malignant Peripheral Nerve Sheath Tumor Using a Dual-Effect Liposome to Combine Photodynamic Therapy and Chemotherapy

et al. 2020

View full text Add to dashboard Cite

Neurofibromatosis type 1 (NF1) is an inherited neurological disorder. Approximately 5–13% of NF1 patients may develop a malignant peripheral nerve sheath tumor (MPNST), which is a neurofibrosarcoma transformed from the plexiform neurofibroma or schwannoma. Given the large size and easy metastasis of MPNST, it remains difficult to be cured by either surgical or conventional chemotherapy. In this study, we investigated the possibility of combining photodynamic therapy (PDT) and chemotherapy to treat MPNST by using a dual-effect liposome (named as PL-cDDP-Ce6), in which a chemotherapeutic agent, cisplatin (cDDP), and photosensitizer, chlorine e6 (Ce6) were encapsulated in the same carrier. The cytotoxic effect of PL-cDDP-Ce6 against MPNST cells was significantly higher than cells treated with liposomal cDDP or Ce6 alone or in combination after light irradiation. Treatment with the dual-effect liposomes in mice bearing xenograft MPNST tumor reveals a significant increase in survival rate compared to those treated with liposomal cDDP and Ce6 in combination. Moreover, there is no weight loss or derangements of serum biochemistry. In conclusion, this study demonstrates the clinical potential and advantage of using this liposomal drug for the treatment of MPNST.

show abstract

The palliative role of PDT in recurrent advanced nasopharyngeal carcinoma: Case series

Cited by 15 publications

References 8 publications

Photodynamic therapy as salvage therapy for patients with nasopharyngeal carcinoma experiencing local failures following definitive radiotherapy

Photodynamic therapy as salvage therapy for patients with nasopharyngeal carcinoma experiencing local failures following definitive radiotherapy

Photochemical Internalization for Intracellular Drug Delivery. From Basic Mechanisms to Clinical Research

A Novel Treatment Modality for Malignant Peripheral Nerve Sheath Tumor Using a Dual-Effect Liposome to Combine Photodynamic Therapy and Chemotherapy

Contact Info

Product

Resources

About